[1]A. fx4 fx2 Gupta, M.V. Madhavan, K. Sehgal, N. Nair, S. Mahajan, T.S. Sehrawat, et al.
Extrapulmonary manifestations of COVID-19.
Nat Med., (2020), 26 pp. 1017-1032
[2]A. Di Minno, P. Ambrosino, I. Calcaterra, M.N.D. Di Minno.
COVID-19 and venous thromboembolism: A meta-analysis of literature studies.
Semin Thromb Hemost., (2020), 46 pp. 763-771
[3]fx4 Morejón P. Coagulopatía y covid-19. SIAC [Internet]. Agosto, 2020. Disponible en: Coagulopatía y covid-19–SIAC (siacardio.com).
[4]Y.J. fx3 Suh, H. Hong, M. Ohana, F. Bompard, M.P. Revel, C. Valle, et al.
Pulmonary embolism and deep vein thrombosis in COVID-19: A systematic review and meta-analysis.
Radiology., (2021), 298 pp. E70-E80
[5]C. fx7 Agbuduwe, S. Basu.
Haematological manifestations of COVID-19: From cytopenia to coagulopathy.
Eur J Haematol., (2020), 105 pp. 540-546
[6]A. fx4 Franco-López, J. Escribano Poveda, N. Vicente Gilabert.
Tromboembolismo pulmonar en los pacientes con COVID-19.
Angiografía computarizada: resultados preliminares. JONNPR [online]., (2020), 5 pp. 616-630
[7]A. fx6 fx1 Cuker, E.K. Tseng, R. Nieuwlaat, P. Angchaisuksiri, C. Blair, K. Dane, et al.
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.
Blood Adv., (2021), 5 pp. 872
[8]fx4 fx2 Elkind M, Cucchiara B, Koralnik D, Rabinstein A, Kasner S, Goddeau R. COVID-19: Neurologic complications and management of neurologic conditions [Internet]. Uptodate 2021 [Consultado 19 Ago 2021]. Disponible en: https://www-uptodate-com.
[9]B.C. fx4 Case, C. Yerasi, B.J. Forrestal, C. Shea, H. Rappaport, G.A. Medranda, et al.
Clinical impact and predictors of troponin elevation in patients with COVID-19.
Cardiovasc. Revasc Med., (2021), 33 pp. 41-44
[10]R.P. fx6 Rosovsky, C. Grodzin, R. Channick, G.A. Davis, J.S. Giri, J. Horowitz, et al.
PERT Consortium. Diagnosis and treatment of pulmonary embolism during the coronavirus disease 2019 pandemic: A position paper from the national PERT Consortium.
Chest, (2020), 158 pp. 2590-2601
[11]fx4 fx2 Cuker A, Peyvandi F, Leung L, Tirnauer J. COVID-19: Hypercoagulability [Internet]. Uptodate 2021 [Consultado 19 Ago 2021]. Disponible en: https://www-uptodate-com.
[12]A. fx4 Piera Carbonell, M. Frías Vargas, O. García Vallejo, A. García Lerín, M.A. Cabrera Ferriols, J. Peiró Morant, et al.
COVID-19 y tromboprofilaxis: recomendaciones para nuestra práctica clínica en Atención Primaria [COVID-19 and thromboprophylaxis: Recommendations for our clinical practice in Primary Care].
Semergen., (2020), 46 pp. 479-486
[13]Z. fx4 Varga, A.J. Flammer, P. Steiger, M. Haberecker, R. Andermatt, A.S. Zinkernagel, et al.
Endothelial cell infection and endotheliitis in COVID-19.
Lancet., (2020), 395 pp. 1417-1418
[14]M. fx7 Linschoten, S. Peters, M. van Smeden, L.S. Jewbali, J. Schaap, H.M. Siebelink, et al.
CAPACITY-COVID collaborative consortium. Cardiac complications in patients hospitalised with COVID-19.
Eur Heart J Acute Cardiovasc Care., (2020), 9 pp. 817-823
[15]fx4 Cordero Q, Escuadra M. Miocarditis, evaluación por imagen. Cardioimagen. 2018. Disponible en: http://cardioacademic.org.mx/cardioimagen/tema-mes/item/95-tema-del-mes-miocarditis-evaluacion-por-imagen.
[16]fx4 fx2 Caforio A, Mancini D, Yeon S. COVID-19: Cardiac manifestations in adults [Internet]. Uptodate 2021 [Consultado 19 Ago 2021]. Disponible en: https://www-uptodate-com.
[17]A. fx4 Singh, S. Zaheer, N. Kumar, T. Singla, S. Ranga.
Covid19, beyond just the lungs: A review of multisystemic involvement by Covid19.
Pathol Res Pract., (2021), 224 pp. 153384
[18]fx4 fx2 Caforio A, Mancini D, Yeon S. COVID-19: Evaluation and management of cardiac disease in adults [Internet]. Uptodate 2021 [Consultado 25 Ago 2021]. Disponible en: https://www-uptodate-com.
[19]F.G. fx4 De Felice, F. Tovar-Moll, J. Moll, D.P. Munoz, S.T. Ferreira.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system.
Trends Neurosci., (2020), 43 pp. 355-357
[20]S.H. fx4 Chou, E. Beghi, R. Helbok, E. Moro, J. Sampson, V. Altamirano, et al.
Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium.
JAMA Netw Open, (2021), 4 pp. e2112131
[21]E.M. fx4 Liotta, A. Batra, J.R. Clark, N.A. Shlobin, S.C. Hoffman, Z.S. Orban, et al.
Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients.
Ann Clin Transl Neurol., (2020), 7 pp. 2221-2230
[22]L. fx4 Mao, H. Jin, M. Wang, Y. Hu, S. Chen, Q. He, et al.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan.
China. JAMA Neurol., (2020), 77 pp. 683-690
[23]J.R. fx4 Lechien, C.M. Chiesa-Estomba, D.R. De Siati, M. Horoi, S.D. Le Bon, A. Rodriguez, et al.
Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.
Eur Arch Otorhinolaryngol., (2020), 277 pp. 2251
[24]M. fx4 Renaud, C. Thibault, F. Le Normand, E.G. Mcdonald, B. Gallix, C.V. Debry, et al.
Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis.
JAMA Netw Open, (2021), 4 pp. e2115352
[25]P. fx4 Zuberbühler, M.E. Conti, L. León-Cejas, F. Maximiliano-González, P. Bonardo, A. Miquelini, et al.
Guillain-Barre syndrome associated to COVID-19 infection: a review of published case reports.
Rev Neurol., (2021), 72 pp. 203-212
[26]R.H. fx4 Hunt, J.E. East, A. Lanas, P. Malfertheiner, J. Satsangi, C. Scarpignato, et al.
COVID-19 and gastrointestinal disease: Implications for the gastroenterologist.
Dig Dis., (2021), 39 pp. 119-139
[27]K.S. fx3 fx1 Cheung, I.F. Hung, P.P. Chan, K.C. Lung, E. Tso, R. Liu, et al.
Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis.
Gastroenterology., (2020), 159 pp. 81-95
[28]D. fx7 Tian, Q. Ye.
Hepatic complications of COVID-19 and its treatment.
J Med Virol., (2020), 92 pp. 1818-1824
[29]H.M.A. fx4 fx1 Kaafarani, M. El Moheb, J.O. Hwabejire, L. Naar, M.A. Christensen, K. Breen, et al.
Gastrointestinal complications in critically Ill patients with COVID-19.
Ann Surg., (2020), 272 pp. e61
[30]A.S. fx4 Eldaly, A.R. Fath, S.M. Mashaly, M. Elhadi.
Acute pancreatitis associated with severe acute respiratory syndrome coronavirus-2 infection: a case report and review of the literature.
J Med Case Rep., (2021), 15 pp. 461
[31]fx4 fx2 Kaafarani H, Weiser M, Chen Wenliang. COVID-19: Gastrointestinal symptoms and complications [Internet]. Uptodate 2021 [Consultado 25 Ago 2021]. Disponible en: https://www-uptodate-com.
[32]R.M. fx4 Gartland, G.C. Velmahos.
Bowel necrosis in the setting of COVID-19.
J Gastrointest Surg., (2020), 24 pp. 2888
[33]L. fx4 Chan, K. Chaudhary, A. Saha, K. Chauhan, A. Vaid, S. Zhao, et al.
AKI in hospitalized patients with COVID-19.
J Am Soc Nephrol., (2021), 32 pp. 151-160
[34]fx4 Vargas JG, Avila N, Hurtado D, Cárdenas-Roldán J, Peña D, Ortiz G. Lesión renal aguda en COVID-19: puesta al día y revisión de la literatura [Acute kidney injury in COVID-19: update and literature review] [published online ahead of print, 2020 Nov 12]. Acta Colomb Cuid Intensivo. 2020. doi:10.1016/j.acci.2020.10.004.
[35]R. fx4 Pal, M. Banerjee.
COVID-19 and the endocrine system: exploring the unexplored.
J Endocrinol Invest., (2020), 43 pp. 1027-1031
[36]J. fx4 Li, X. Wang, J. Chen, X. Zuo, H. Zhang, A. Deng.
COVID-19 infection may cause ketosis and ketoacidosis.
Diabetes Obes Metab., (2020), 22 pp. 1935-1941
[37]G. fx4 Genovese, C. Moltrasio, E. Berti, A. Marzano.
Skin manifestations associated with COVID-19: Current knowledge and future perspectives.
Dermatology, (2021), 237 pp. 1-12
[38]F. fx4 Pérez-Bartolomé, J. Sánchez-Quirós.
Ocular manifestations of SARS-CoV-2: Literature review.
Arch Soc Esp Oftalmol (Engl Ed)., (2021), 96 pp. 32-40
[39]A. fx4 Nalbandian, K. Sehgal, A. Gupta, M.V. Madhavan, C. McGroder, J.S. Stevens, et al.
Post-acute COVID-19 syndrome.
Nat Med., (2021), 27 pp. 601-615
[40]fx4 WHO scientific brief. Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2. February 8, 2021 https://www.who.int/publications/i/item/WHO-2019-nCoV-mother-to-child-transmission-2021.1 [Consultado 11 Feb 2021].
[41]fx4 Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al., Update: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:1641.
[42]fx4 fx2 Berghella V, Hughes B, Lockwood C, Barss V. COVID-19: Pregnancy issues and antenatal care [Internet]. Uptodate 2021 [Consultado 26 Ago 2021]. Disponible en: https://www-uptodate-com.
[43]fx4 fx1 Deville JG, Song E, Ouellette CP. COVID-19: Clinical manifestations and diagnosis in children [Internet]. Uptodate 2021 [Consultado 19 Sep 2021]. Disponible en: https://www-uptodate-com.
[44]fx4 Son MBF, Friedman K. COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome [Internet]. Up-todate 2021 [Consultado 18 Sep 2021]. Disponible en: https://www-uptodate-com.